Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment

Claudia Gagnon, Vivien Li, Peter R EbelingDepartment of Medicine, University of Melbourne, Melbourne, AustraliaAbstract: As the population ages, the burden of osteoporosis in men is expected to rise. Implementation of preventive measures such as falls prevention strategies, exercise and adequate cal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claudia Gagnon, Vivien Li, Peter R Ebeling
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Osteoporosis treatment parathyroid hormone men Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/5539da270b0746c3a4a01fced688dd9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5539da270b0746c3a4a01fced688dd9e
record_format	dspace
spelling	oai:doaj.org-article:5539da270b0746c3a4a01fced688dd9e2021-12-02T00:31:07ZOsteoporosis in men: its pathophysiology and the role of teriparatide in its treatment1178-1998https://doaj.org/article/5539da270b0746c3a4a01fced688dd9e2008-12-01T00:00:00Zhttps://www.dovepress.com/osteoporosis-in-men-its-pathophysiology-and-the-role-of-teriparatide-i-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Claudia Gagnon, Vivien Li, Peter R EbelingDepartment of Medicine, University of Melbourne, Melbourne, AustraliaAbstract: As the population ages, the burden of osteoporosis in men is expected to rise. Implementation of preventive measures such as falls prevention strategies, exercise and adequate calcium and vitamin D intake is recommended. However, when the diagnosis of osteoporosis is made, effective treatments need to be initiated to prevent fractures. As opposed to postmenopausal women, reduced bone formation is the predominant mechanism of age-related bone loss in men, making anabolic agents a logical treatment option for men with osteoporosis. Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in men. This paper summarizes the mechanism of action of teriparatide, as well as its tolerability and safety. Furthermore, the evidence supporting the efficacy of teriparatide treatment in men with osteoporosis is reviewed and its current role in the management of osteoporosis in men is discussed.Keywords: osteoporosis, pathophysiology, treatment, parathyroid hormone, menClaudia GagnonVivien LiPeter R EbelingDove Medical PressarticleOsteoporosistreatmentparathyroid hormonemenGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 635-645 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Osteoporosis treatment parathyroid hormone men Geriatrics RC952-954.6
spellingShingle	Osteoporosis treatment parathyroid hormone men Geriatrics RC952-954.6 Claudia Gagnon Vivien Li Peter R Ebeling Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
description	Claudia Gagnon, Vivien Li, Peter R EbelingDepartment of Medicine, University of Melbourne, Melbourne, AustraliaAbstract: As the population ages, the burden of osteoporosis in men is expected to rise. Implementation of preventive measures such as falls prevention strategies, exercise and adequate calcium and vitamin D intake is recommended. However, when the diagnosis of osteoporosis is made, effective treatments need to be initiated to prevent fractures. As opposed to postmenopausal women, reduced bone formation is the predominant mechanism of age-related bone loss in men, making anabolic agents a logical treatment option for men with osteoporosis. Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in men. This paper summarizes the mechanism of action of teriparatide, as well as its tolerability and safety. Furthermore, the evidence supporting the efficacy of teriparatide treatment in men with osteoporosis is reviewed and its current role in the management of osteoporosis in men is discussed.Keywords: osteoporosis, pathophysiology, treatment, parathyroid hormone, men
format	article
author	Claudia Gagnon Vivien Li Peter R Ebeling
author_facet	Claudia Gagnon Vivien Li Peter R Ebeling
author_sort	Claudia Gagnon
title	Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
title_short	Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
title_full	Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
title_fullStr	Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
title_full_unstemmed	Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
title_sort	osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/5539da270b0746c3a4a01fced688dd9e
work_keys_str_mv	AT claudiagagnon osteoporosisinmenitspathophysiologyandtheroleofteriparatideinitstreatment AT vivienli osteoporosisinmenitspathophysiologyandtheroleofteriparatideinitstreatment AT peterrebeling osteoporosisinmenitspathophysiologyandtheroleofteriparatideinitstreatment
_version_	1718403675178663936

Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment

Ejemplares similares